These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 32154149)

  • 21. Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1.
    Li YM; Zhang LH; Li XJ; Zhang B; Hou JN; Tong NW
    Diabetes Ther; 2020 May; 11(5):1077-1090. PubMed ID: 32219675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptin.
    Farr AM; Sheehan JJ; Davis BM; Smith DM
    Patient Prefer Adherence; 2016; 10():1471-9. PubMed ID: 27540280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors.
    Zhang Y; Wu M; Htun W; Dong EW; Mauvais-Jarvis F; Fonseca VA; Wu H
    Sci Rep; 2017 Aug; 7(1):7964. PubMed ID: 28801559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Healthcare costs among adults with type 2 diabetes initiating saxagliptin or linagliptin: a US-based claims analysis.
    Kong AM; Farahbakhshian S; Pendergraft T; Brouillette MA; Mukherjee B; Smith DM; Sheehan JJ
    Curr Med Res Opin; 2017 Oct; 33(10):1869-1877. PubMed ID: 28613952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.
    Lingvay I; Beetz N; Sennewald R; Schuler-Metz A; Bertulis J; Loley C; Lang B; Lippert C; Lee J; Manning LS; Terada D
    Postgrad Med; 2020 May; 132(4):337-345. PubMed ID: 32366156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial.
    Biessels GJ; Verhagen C; Janssen J; van den Berg E; Zinman B; Rosenstock J; George JT; Passera A; Schnaidt S; Johansen OE;
    Diabetes Care; 2019 Oct; 42(10):1930-1938. PubMed ID: 31399442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria.
    Cooper ME; Perkovic V; Groop PH; Hocher B; Hehnke U; Meinicke T; Koitka-Weber A; van der Walt S; von Eynatten M
    J Hypertens; 2019 Jun; 37(6):1294-1300. PubMed ID: 30540657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ
    Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation, efficacy and tolerability of GlucoNovax tablet in type 2 diabetic patients.
    Ali Z; Daniyal M; S I I; Usmanghani K; Naveed S
    Pak J Pharm Sci; 2016 Jul; 29(4 Suppl):1443-9. PubMed ID: 27592478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.
    Fujimoto K; Shibayama Y; Yamaguchi E; Honjo S; Hamasaki A; Hamamoto Y
    J Diabetes; 2018 Aug; 10(8):675-682. PubMed ID: 29493100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
    Hanssen NM; Jandeleit-Dahm KA
    Diab Vasc Dis Res; 2019 Jul; 16(4):303-309. PubMed ID: 31018682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.
    Li YR; Tsai SS; Chen DY; Chen ST; Sun JH; Chang HY; Liou MJ; Chen TH
    Cardiovasc Diabetol; 2018 Jan; 17(1):2. PubMed ID: 29301579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Linagliptin as add-on therapy for type 2 diabetes - an overview.
    Brown DX; Choudhury M; Evans M
    Drugs Today (Barc); 2012 Oct; 48(10):645-54. PubMed ID: 23110260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linagliptin for the treatment of type 2 diabetes.
    Del Prato S
    Expert Opin Pharmacother; 2011 Dec; 12(17):2759-62. PubMed ID: 21883034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease.
    Kosaraju J; Holsinger RMD; Guo L; Tam KY
    Mol Neurobiol; 2017 Oct; 54(8):6074-6084. PubMed ID: 27699599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.
    Lee WC; Conner C; Hammer M
    Curr Med Res Opin; 2011 May; 27(5):897-906. PubMed ID: 21348806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia.
    Holstein A; Plaschke A; Hammer C; Egberts EH
    Eur J Clin Pharmacol; 2003 Jun; 59(2):91-7. PubMed ID: 12698302
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.